GlassScriptPhysician profile
Amareshwar Chiruvella
NPI 1154641157
$8,695.34
in general payments reported to CMS, 2019-2025
12 companies · $6,344 in 2025
The $6,344 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $12.98 · 2021: $37.86 · 2022: $16.12 · 2023: $106 · 2024: $2,063 · 2025: $6,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,348 · Travel and Lodging: $2,636 · Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,348.08 |
| Travel and Lodging | $2,636.09 |
| Food and Beverage | $1,528.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,190.69 | 2024-2025 | |
| Medtronic, INC. | $730.53 | 2024-2025 | Signia, Ligasure, Plasmablade(Tm) |
| Echosens North America, INC. | $149.38 | 2025 | Fibroscan |
| Tela Bio, INC. | $145.33 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Becton, Dickinson and Company | $105.84 | 2023 | Phasix Mesh |
| Allergan, INC. | $102.43 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $101.68 | 2024 | Imcivree |
| Sanara Medtech INC. | $89.13 | 2025 | Celleraterx |
| Olympus America INC. | $26.35 | 2019-2020 | |
| Organogenesis INC. | $24.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.12 | 2022 | |
| Braintree Laboratories, INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amareshwar Chiruvella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.